AI-powered cervical cancer screening device achieved 42% sales growth in FY26, with over 1 million women screened globally and strong clinical validation. Focused on LMICs, the company leverages partnerships and a recurring revenue model to capture a growing share of the $7.9bn market.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.